MacroGenics Inc ((MGNX)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
MacroGenics Inc. is conducting a Phase 1 clinical trial titled A Phase 1, First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC028 in Participants With Advanced Solid Tumors. The study aims to evaluate the safety, tolerability, and optimal dosing of MGC028, an antibody-drug conjugate targeting ADAM9, in patients with advanced solid tumors. The primary objective is to identify potential side effects and assess the drug’s ability to control tumor progression.
MGC028, the intervention being tested, is a biological treatment designed to target and combat advanced solid tumors by leveraging its action against the ADAM9 protein.
The study follows a non-randomized, sequential intervention model with no masking, focusing primarily on treatment. Participants are divided into multiple cohorts to receive varying doses of MGC028, with the goal of determining the maximum tolerated dose.
The study began on December 4, 2024, with the latest update submitted on September 16, 2025. These dates are crucial as they mark the progression and current status of the trial, which is still recruiting participants.
This study update could influence MacroGenics’ stock performance by potentially boosting investor confidence if the results show promise in treating advanced solid tumors. It also positions MacroGenics competitively within the oncology sector, where advancements in targeted therapies are highly sought after.
The study is ongoing, with further details available on the ClinicalTrials portal.